Management of Decompensated HCV Cirrhotic Patients
Status:
Completed
Trial end date:
2018-06-24
Target enrollment:
Participant gender:
Summary
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV)
remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with
complications as worsening decompensation. The impact of DAAs therapy on mortality in
decompensated cirrhosis was not investigated.
Phase:
N/A
Details
Lead Sponsor:
Zagazig University
Treatments:
Antiviral Agents Furosemide Ribavirin Silymarin Sofosbuvir Spironolactone Vitamin K Vitamin K 1